CYP2D6*10和CYP2C19*2基因型多态性与接受他莫昔芬治疗乳腺癌患者生存率的相关性研究

中国临床药理学与治疗学 ›› 2015, Vol. 20 ›› Issue (5): 552-556.

CYP2D6^10和CYP2C19^2基因型多态性与接受他莫昔芬治疗乳腺癌患者生存率的相关性研究

王莹莹¹, 程光华¹, 濮之晨², 葛俊亮¹, 谢彦¹, 陈晓磊¹

¹皖南医学院弋矶山医院核医学科, ²皖南医学院弋矶山医院临床药学部, 芜湖 241000,安徽

收稿日期:2014-03-25 修回日期:2014-10-10 发布日期:2015-06-11
通讯作者: 程光华,男,副教授,硕士生导师,研究方向:核素显像与治疗。Tel: 13855399867 E-mail: cgh892@yahoo.com.cn
作者简介:王莹莹,女,硕士在读,研究方向:核素显像与治疗。E-mail: wyy850247303@sina.com

Association between CYP2D6^10/CYP2C19^2 genotype polymorphism and survival of breast cancer patients receiving tamoxifen treatment

WANG Ying-ying¹, CHENG Guang-hua¹, PU Zhi-chen², GE Jun-liang¹, XIE Yan¹, CHEN Xiao-lei¹

¹ Department of Nuclear Medicine, Yijishan Hospital, Wannan Medical College, ² Department of Clinical Medicine, Yijishan Hospital, Wannan Medical College, Wuhu 241001, Anhui, China

Received:2014-03-25 Revised:2014-10-10 Published:2015-06-11

摘要/Abstract

摘要： 目的: 研究CYP2D6^*10和CYP2C19^*2基因型多态性与接受他莫昔芬(tamoxifen, TAM)治疗乳腺癌患者生存率的相关性研究。方法: 选择2009至2004年本院甲乳外科和肿瘤内科收治的171名术后服用TAM治疗的雌激素阳性乳腺癌患者,调查TAM使用情况和生存状态等相关资料;收集相关的石蜡组织切片用于DNA提取;用PCR技术检测CYP2D6^*10和CYP2C19^*2基因型多态性;查明CYP2D6^*10和CYP2C19^*2基因型多态性与患者生存率的相关性。结果: 本次研究中,CYP2D6Wt/Wt、CYP2D6Wt/^*10和CYP2D6^*10/^*10基因型的总生存率(overall survival,OS)类似,差异无统计学意义(P>0.05)。CYP2C19^*2/^*2基因型的5年OS明显优于CYP2C19 Wt/Wt,差异具有统计学意义(P<0.05);CYP2C19^*2/^*2基因型的10年OS明显优于CYP2C19 Wt/Wt和CYP2C19 Wt/^*2,差异具有统计学意义(P<0.05);但是CYP2C19Wt/Wt与CYP2C19 Wt/^*2的5、10年OS差异无统计学意义(P>0.05)。结论: 研究结果显示,CYP2D6^*10基因型多态性与服用TAM治疗乳腺癌患者的生存率之间不存在相关性;CYP2C19^*2基因型多态性与接受TAM治疗乳腺癌患者的生存率之间存在相关性,CYP2C19^*2/^*2接受TAM治疗乳腺癌患者的生存率最高,CYP2C19 Wt/^*2生存率较高,CYP2C19 Wt/Wt较低。

关键词: CYP2D6^*10, CYP2C19^*2, 乳腺癌, 他莫昔芬

Abstract: AIM: To observe the association between CYP2D6^*10 and CYP2C19^*2 genotype polymorphism and survival of breast cancer patient receiving tamoxifen (TAM) treatment.METHODS: 171 cases of breast cancer patient receiving TAM treatment were selected from breast surgery and medical oncology since 2004-2009. The service condition of TAM treatment and the survival state were examined, the paraffin section of patients were collected and used in DNA extract, the CYP2D6^*10 and CYP2C19^*2 genotype polymorphism were detected by PCR, and the association between CYP2D6^*10 and CYP2C19^*2 genotype polymorphism and survival of breast cancer patient receiving TAM treatment were ascertained.RESULTS: Overall survival (OS) of CYP2D6Wt/Wt, CYP2D6Wt/^*10 and CYP2D6^*10/^*10 were very similar (P>0.05). 5 years-OS of CYP2C19^*2/^*2 were significantly higher than that of CYP2C19 Wt/Wt group, and the difference was statistically significant (P<0.05); 10 years-OS of CYP2C19^*2/^*2 were significantly higher than that of CYP2C19 Wt/Wt or CYP2C19 Wt/^*2,and the difference was statistically significant (P<0.05); 5 or 10 years-OS of CYP2C19 Wt/Wt was similar to that of CYP2C19 Wt/^*2 (P>0.05).CONCLUSION: The CYP2D6^*10 genotype polymorphisms isn't associated with survival of breast cancer patient receiving TAM treatment. The CYP2C19^*2 genotype polymorphism is associated with survival of breast cancer patient receiving TAM treatment. The survival rate of breast cancer patient with CYP2C19^*2/^*2 receiving TAM treatment is the highest, that of CYP2C19 Wt/^*2 is medium, and that of CYP2C19 Wt/Wt is lower.

Key words: CYP2D6^*10, CYP2C19^*2, breast cancer, tamoxifen

中图分类号:

R737.9

王莹莹, 程光华, 濮之晨, 葛俊亮, 谢彦, 陈晓磊. CYP2D6^*10和CYP2C19^*2基因型多态性与接受他莫昔芬治疗乳腺癌患者生存率的相关性研究[J]. 中国临床药理学与治疗学, 2015, 20(5): 552-556.

WANG Ying-ying, CHENG Guang-hua, PU Zhi-chen, GE Jun-liang, XIE Yan, CHEN Xiao-lei. Association between CYP2D6^*10/CYP2C19^*2 genotype polymorphism and survival of breast cancer patients receiving tamoxifen treatment[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 552-556.

参考文献

[1] 濮之晨, 王五三, 徐喆, 等. 基因多态性对他莫昔芬治疗乳腺癌的影响与个体化用药进[J]. 安徽医药, 2013, 17(7): 1083-1085.
[2] 胡东莉, 陈尧, 沈杰, 等. UPLC-MS/MS同时测定血浆样品中他莫昔芬及代谢产物的浓度和应用[J]. 中国临床药理学与治疗学, 2012, 17(7): 773-780.
[3] Beelen K, Opdam M, Severson TM, et al. CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment [J]. Breast Cancer Res Treat, 2013, 139(3): 649-655.
[4] Markiewicz A, Wełnicka-Ja$\hat{s}$kiewicz M, Skokowski J, et al. Prognostic significance of ESR1 amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients [J]. PLoS One, 2013, 8(8): e72219.
[5] Chamnanphon M, Pechatanan K, Sirachainan E, et al. Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen [J]. Pharmgenomics Pers Med, 2013, 24 (6): 37-48.
[6] Ruiter R, Bijl MJ, van Schaik RH, et al. CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen [J]. Pharmacogenomics, 2010, 11(10): 1367-1375.
[7] 陈冰, 蔡卫民, 杨婉花. CYP2D6基因多态性与抗精神病药物的个体化应用[J]. 中国临床药理学与治疗学, 2012, 17(9): 1067-1070.
[8] Okishiro M, Taguchi T, Jin Kim S, et al. Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen [J]. Cancer, 2009, 115(5): 952-961.
[9] Hayes DF, Stearns V, Rae J, et al. A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients [J]. J Natl Cancer Inst, 2008, 100 (9): 610-613.
[10]谢彦, 刘璐, 张俊, 等. 环九肽与人乳腺癌MDA-MB-231细胞特异性结合的研究[J]. 中国临床药理学与治疗学, 2014, 19(6): 615-620.
[11]黄征宇, 刘芳群, 高利臣, 等. 乳腺癌环磷酰胺治疗的药物基因组学研究进展[J]. 中国临床药理学与治疗学, 2014, 19(10): 1196-1200.
[12]Moyer AM, Suman VJ, Weinshilboum RM, et al. SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen [J]. Pharmacogenomics, 2011, 12(11): 1535-1543.

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[3]	付晓玉, 孔德光, 李娟娟. 三阳性乳腺癌的治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 866-875.
[4]	罗师萍, 张捷, 俞育帅, 宋传贵. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 876-886.
[5]	向奕玫, 张宁宁, 黄雨昕, 曾晓华. HER2阳性乳腺癌疗效相关生物标志物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 887-897.
[6]	陈柯羽, 黄圆, 王晓稼, 郑亚兵. 抗体偶联药物在乳腺癌中的临床应用与研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 898-909.
[7]	李梦茜, 张克兢, 夏凡. 乳腺癌疫苗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 918-925.
[8]	王智, 周鑫, 何雪茹, 付裕豪, 荀雪姣, 李颖, 董占军. 哌柏西利治疗乳腺癌的临床研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 205-213.
[9]	王秀, 季麒麟, 裴文俊, 曾颖. 3-溴丙酮酸-胆固醇酯增强乳腺癌细胞对他莫昔芬敏感性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1093-1100.
[10]	武帅, 杨君, 郑云. 乳腺癌中具有双重功能的miRNA[J]. 中国临床药理学与治疗学, 2022, 27(7): 814-821.
[11]	施经斌, 熊阳. 肿瘤微环境与乳腺癌细胞互作导致肿瘤转移的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(5): 562-574.
[12]	董伟, 黄小英, 谢冰斌, 汤喜兰, 李洪铭, 邱雨美, 赵国巍, 梁新丽. 氧化前胡素对乳腺癌MCF-7/DOX细胞多柔比星耐药的抑制作用[J]. 中国临床药理学与治疗学, 2022, 27(3): 260-266.
[13]	徐国防, 张思森, 刘平, 梅家转, 刘玮玮, 刘亚欧, 齐琦. 卡培他滨在中国乳腺癌患者中的群体药代动力学研究[J]. 中国临床药理学与治疗学, 2021, 26(5): 552-559.
[14]	孙红, 侯佳林, 蔡加琴, 魏晓霞, 庄捷. SUMO E3连接酶介导雄激素受体的转录促进乳腺癌他莫昔芬耐药[J]. 中国临床药理学与治疗学, 2021, 26(3): 285-291.
[15]	金乐, 蒋多晨, 陈洪晓, 刘苏, 陈昭琳, 居靖. 槲皮素通过GAS5调控GSK-3β/β-catenin逆转乳腺癌阿霉素耐药[J]. 中国临床药理学与治疗学, 2021, 26(12): 1344-1351.